Avadel Pharmaceuticals plc
AVDLNASDAQHealthcare
$21.64
+$0.00(+0.00%)
Market Cap$2.1B
P/E Ratio—
52W High$23.57
52W Low$6.38
Avadel Pharmaceuticals plc (AVDL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AVDL · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 2, 2026EPS Actual
-$0.05
Est. $0.08 · -162.5%
Revenue
—
Est. $0.08B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 2, 2026
After Market Close
▼ Miss EPS
AVDL reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 2, 2026 | $0.08 | -$0.05 | -162.5% | — | $0.08B | — |
| ◌ Q4 FY2025 | Nov 4, 2025 | $0.04 | — | — | $0.08B | $0.08B | -3.5% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.02 | $0.10 | +400.0% | $0.07B | $0.07B | -7.4% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.07 | -$0.05 | +28.6% | $0.05B | $0.06B | -9.8% |
| — Q1 FY2025 | Mar 3, 2025 | -$0.05 | -$0.05 | +0.0% | $0.05B | $0.05B | -4.1% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.06 | -$0.03 | +50.0% | $0.05B | $0.05B | -5.1% |
| ▲ Q3 FY2024 | Aug 8, 2024 | -$0.17 | -$0.14 | +17.6% | $0.04B | $0.05B | -14.0% |
| ▼ Q2 FY2024 | May 8, 2024 | -$0.25 | -$0.30 | -20.0% | $0.03B | $0.04B | -27.7% |
Q1 FY2026
Mar 2, 2026Miss
EPS Actual
-$0.05
EPS Est.
$0.08
EPS Surpr.
-162.5%
Revenue
—
Q4 FY2025
Nov 4, 2025
EPS Actual
—
EPS Est.
$0.04
EPS Surpr.
—
Revenue
$0.08B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.10
EPS Est.
$0.02
EPS Surpr.
+400.0%
Revenue
$0.07B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.07
EPS Surpr.
+28.6%
Revenue
$0.05B
Q1 FY2025
Mar 3, 2025
EPS Actual
-$0.05
EPS Est.
-$0.05
EPS Surpr.
+0.0%
Revenue
$0.05B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.03
EPS Est.
-$0.06
EPS Surpr.
+50.0%
Revenue
$0.05B
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.17
EPS Surpr.
+17.6%
Revenue
$0.04B
Q2 FY2024
May 8, 2024Miss
EPS Actual
-$0.30
EPS Est.
-$0.25
EPS Surpr.
-20.0%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.25 | $0.25 | $0.25 | 1 |
| Q3 FY2027 | $0.21 | $0.21 | $0.21 | 1 |
| Q2 FY2027 | $0.19 | $0.19 | $0.19 | 1 |
| Q1 FY2027 | $0.15 | $0.15 | $0.15 | 1 |
| Q4 FY2026 | $0.21 | $0.21 | $0.21 | 1 |
| Q3 FY2026 | $0.19 | $0.19 | $0.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 2, 2026 | -162.5% | $21.64 | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | +400.0% | $11.10 | $12.74 | +14.77% |
| ▲ Q2 FY2025 | May 7, 2025 | +28.6% | $8.64 | $9.47 | +9.61% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +0.0% | $7.91 | $7.55 | -4.55% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +50.0% | $16.30 | $13.15 | -19.33% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +17.6% | $16.10 | $15.74 | -2.24% |
| ▼ Q2 FY2024 | May 8, 2024 | -20.0% | $18.18 | $16.25 | -10.62% |
| ▼ Q1 FY2024 | Mar 4, 2024 | -14.3% | $13.72 | $16.13 | +17.57% |
Q1 FY2026—
Report Date
Mar 2, 2026
EPS Beat/Miss
-162.5%
Price Before
$21.64
Price After
—
Q3 FY2025+14.77%
Report Date
Aug 7, 2025
EPS Beat/Miss
+400.0%
Price Before
$11.10
Price After
$12.74
Q2 FY2025+9.61%
Report Date
May 7, 2025
EPS Beat/Miss
+28.6%
Price Before
$8.64
Price After
$9.47
Q1 FY2025-4.55%
Report Date
Mar 3, 2025
EPS Beat/Miss
+0.0%
Price Before
$7.91
Price After
$7.55
Q4 FY2024-19.33%
Report Date
Nov 12, 2024
EPS Beat/Miss
+50.0%
Price Before
$16.30
Price After
$13.15
Q3 FY2024-2.24%
Report Date
Aug 8, 2024
EPS Beat/Miss
+17.6%
Price Before
$16.10
Price After
$15.74
Q2 FY2024-10.62%
Report Date
May 8, 2024
EPS Beat/Miss
-20.0%
Price Before
$18.18
Price After
$16.25
Q1 FY2024+17.57%
Report Date
Mar 4, 2024
EPS Beat/Miss
-14.3%
Price Before
$13.72
Price After
$16.13
Avg Beat Reaction-0.35%
Avg Miss Reaction+3.48%
Beat Rate5 / 8 quarters
Largest Move-19.33% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AVDL ends December
Avadel Pharmaceuticals plc (AVDL) most recently reported earnings on March 2, 2026 for Q1 FY2026, posting EPS of $-0.05 — missing the analyst consensus of $0.08 by -162.5%. The next AVDL earnings date is expected around September 1, 2026.
Each quarter, investors track AVDL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AVDL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AVDL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AVDL earnings · 5 questionsAvadel Pharmaceuticals plc's next earnings report is expected around September 1, 2026. AVDL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AVDL historically reports after market close (AMC).
AVDL earnings datewhen is AVDL earningsAVDL next earnings datewhen does AVDL report earningsAVDL earnings calendar
▸ Source: FMP · Avadel Pharmaceuticals plc SEC filings · US GAAP · Avadel Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026